EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Adjunctive Pascolizumab in Rifampicin-Susceptible Pulmonary Tuberculosis: Proof-of-Concept, Partially-Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial

Nicholas I Paton iD, Meera Gurumurthy, Qingshu Lu, Francesca Leek, Philip Kwan, Hiromi W L Koh, James Molton, Lalaine Mortera, Sullian Naval, Zamzurina Abu Bakar, Yong-Kek Pang, Lionel Lum und 9 weitere

The Journal of Infectious Diseases · 2024

DOI: 10.1093/infdis/jiae104 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Nicholas I Paton und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. Hauptthemen laut MEDLINE: Tuberculosis, Pulmonary, Rifampin, Antibodies, Monoclonal, Humanized, Interleukin-4. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: Singapore Ministry of Health, GSK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Interleukin 4 (IL-4), increased in tuberculosis infection, may impair bacterial killing. Blocking IL-4 confers benefit in animal models. We evaluated safety and efficacy of pascolizumab (humanized anti–IL-4 monoclonal antibody) as adjunctive tuberculosis treatment.

Methods

Participants with rifampicin-susceptible pulmonary tuberculosis received a single intravenous infusion of pascolizumab or placebo, and standard 6-month tuberculosis treatment. Pascolizumab dose increased in successive cohorts: (1) nonrandomized 0.05 mg/kg (n = 4); (2) nonrandomized 0.5 mg/kg (n = 4); (3) randomized 2.5 mg/kg (n = 9) or placebo (n = 3); and (4) randomized 10 mg/kg (n = 9) or placebo (n = 3). Coprimary safety outcome was study-drug–related grade 4 or serious adverse event (G4/SAE) in all cohorts (1–4). Coprimary efficacy outcome was week 8 sputum culture time-to-positivity (TTP) in randomized cohorts (3–4) combined.

Results

Pascolizumab levels exceeded IL-4 50% neutralizing dose for 8 weeks in 78%–100% of participants in cohorts 3–4. There were no study-drug–related G4/SAEs. Median week-8 TTP was 42 days in pascolizumab and placebo groups (P = .185). Rate of TTP increase was greater with pascolizumab (difference from placebo 0.011 log10 TTP/day; 95% Bayesian credible interval 0.006 to 0.015 log10 TTP/day).

Conclusions

There was no evidence to suggest blocking IL-4 was unsafe. Preliminary efficacy findings are consistent with animal models. This supports further investigation of adjunctive anti–IL-4 interventions for tuberculosis in larger phase 2 trials. Clinical Trials Registration NCT 01638520.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tuberculosis, PulmonaryRifampinAntibodies, Monoclonal, HumanizedInterleukin-4HumansDouble-Blind MethodAdultFemaleMaleMiddle AgedAntitubercular AgentsTreatment OutcomeYoung AdultProof of Concept StudyDrug Therapy, CombinationDose-Response Relationship, DrugPlacebos

Stichwörter der Autor:innen

clinical trialhost-directed therapyinterleukin-4pascolizumabtuberculosis

Substanzen

RifampinAntibodies, Monoclonal, HumanizedInterleukin-4Antitubercular AgentsPlacebos

Autor:innen und Institutionen

  • Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Infectious Diseases Translational Research Programme, National University of Singapore, Singapore, Singapore.
  • Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Singapore Clinical Research Institute, Singapore, Singapore, Singapore.
  • Clinical Imaging Research Centre, National University of Singapore, Singapore, Singapore.
  • Quezon Institute, Quezon City, Philippines.

ORCID-Profile: Nicholas I Paton, Hyungwon Choi

Förderung

  • Singapore Ministry of Health
  • GSK

Zitieren

APA

Paton, N. I., Gurumurthy, M., Lu, Q., Leek, F., Kwan, P., Koh, H. W. L., Molton, J., Mortera, L., Naval, S., Bakar, Z. A., Pang, Y. K., Lum, L., Lim, T. K., Cross, G. B., Lekurwale, G., Choi, H., Au, V., Connolly, J., Hibberd, M., …, & Pascolizumab Tuberculosis Trial Team (2024). Adjunctive Pascolizumab in Rifampicin-Susceptible Pulmonary Tuberculosis: Proof-of-Concept, Partially-Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae104

Vancouver

Paton NI, Gurumurthy M, Lu Q, Leek F, Kwan P, Koh HWL, et al. Adjunctive Pascolizumab in Rifampicin-Susceptible Pulmonary Tuberculosis: Proof-of-Concept, Partially-Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiae104

BibTeX
@article{Paton2024,
  author = {Paton, Nicholas I and Gurumurthy, Meera and Lu, Qingshu and Leek, Francesca and Kwan, Philip and Koh, Hiromi W L and Molton, James and Mortera, Lalaine and Naval, Sullian and Bakar, Zamzurina Abu and Pang, Yong-Kek and Lum, Lionel and Lim, Tow Keang and Cross, Gail B and Lekurwale, Ganesh and Choi, Hyungwon and Au, Veonice and Connolly, John and Hibberd, Martin and Green, Justin A and Pascolizumab Tuberculosis Trial Team, Pascolizumab Tuberculosis Trial Team},
  title = {Adjunctive Pascolizumab in Rifampicin-Susceptible Pulmonary Tuberculosis: Proof-of-Concept, Partially-Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial},
  journal = {The Journal of Infectious Diseases},
  year = {2024},
  doi = {10.1093/infdis/jiae104}
}
Kostenlos starten →